Uniphar stock

UPR · Euronext Dublin · EUR

€4.31Change from previous close: +0.58%Absolute change: +€0.02

Close · November 16, 2026

Price history

+14.63% over the period

1 year: from €3.76 (November 17, 2025) to €4.31 (November 16, 2026), +14.63%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026€4.31
October 30, 2026€3.98
September 30, 2026€4.06
August 31, 2026€4.24
July 31, 2026€4.25
June 30, 2026€4.45
May 29, 2026€4.56
April 30, 2026€4.16
March 31, 2026€3.80
February 27, 2026€4.09
January 30, 2026€3.83
December 31, 2025€3.52
November 28, 2025€3.77
November 17, 2025€3.76

At a glance

  • The company

    Diversified healthcare services company providing pharmaceutical and medical device distribution, pharmacy operations, and related support services across Ireland, UK, Netherlands and internationally

  • Latest results

    Quarter to June 30, 2026 · EPS €0.04

TickerLandia's take on Uniphar

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€3.38
52-wk high€4.98

−13.37% from the 52-week high

Analysts · 8 analysts

Average target€5.57+29.21% vs. price

Buy 8 · Hold 0 · Sell 0

TickerLandia Fingerprint: Uniphar

Compared with similar companies: low dividend, low financial strength, and high earnings stability.

Financials and price compared with 11 companies in the medical distribution industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Uniphar is pricier than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Uniphar's P/E today is 22.1, above the median of its last 7 fiscal years (18.1; between 9.02 and 28.1 from 2019 to 2025). Uniphar's P/E (trailing 12 months): 21.4, −24% against the median of a group of 11 similar companies (28.2).

P/E compared with its history

Compared with 11 similar companies

Uniphar's metrics compared with similar companies
MetricUnipharPosition in the groupBand
P/E (trailing 12 months)21.4Middle
Forward P/E15.3Middle
Operating margin2.9%Middle
ROE13.4%Middle
Debt/equity1.22High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Uniphar. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€1.59B

Latest quarter · Q2 2026

Net income

€19.99M

Latest quarter · Q2 2026

Quarterly net margin

1.3%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€1.11B
P/E
21.4
EPS
€0.20
Volume
515.14K
Daily trading
€1.23M
Dividend yield
0.48%
Last ex-dividend on September 17, 2026

How Uniphar is changing

All results
  • Revenue grew 11.0% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 100% of net income

  • Revenue has grown for 8 fiscal years in a row

Returns

Uniphar returns with dividends

€1,000 invested in Uniphar 5 years ago, on November 16, 2021, would be worth €1,007 today with dividends reinvested: +0.67% in total, +0.13% per year. On price alone it would be €977 (−2.27%).

PeriodUniphar€1,000 becomes
1 month+7.75%€1,078
6 months−0.23%€998
Year to date+22.44%€1,224
1 year+15.21%€1,152
3 years+110.53%€2,105
5 years+0.67%€1,007

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Uniphar: technical analysis

Uniphar shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 13.8% below its all-time closing high (€5.00, December 31, 2021).

Trend
No clear trend
RSI (14 sessions)
62
Between 30 and 70
vs 200-session average
+2.26%

Support and resistance

Price areas where Uniphar has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance€4.42+2.44%2 touches, last on November 5, 2026
  2. Resistance€4.35+0.90%5 touches, last on September 8, 2026
  3. Last price€4.31
  4. Support€4.18−2.98%3 touches, last on September 30, 2026
  5. Support€4.12−4.45%6 touches, last on October 15, 2026
  6. Support€3.88−9.92%6 touches, last on October 23, 2026

Volatility and risk

Volatility (60 sessions, annualised)
23.2%
Largest fall in the last year
−21.95%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Uniphar: seasonality

Average monthly price change over 8 years

+3.8%Jan−0.6%Feb−1.0%Mar+7.6%Apr+12.4%May−6.8%Jun+6.8%Jul+1.6%Aug−1.9%Sep−1.2%Oct+0.7%Nov+2.0%Dec

Over the last 8 years, the strongest month for Uniphar has been May: +12.39% on average, positive in 6 years out of 7. The weakest has been June: −6.84% on average, positive in 1 years out of 7. November, the current month, has been positive in 3 years out of 7 (+0.67% on average).

Show chart data
MonthAverageMedianPositive years
January+3.80%+7.14%6 of 7
February−0.56%−2.67%3 of 7
March−0.99%−4.41%3 of 7
April+7.62%+9.02%6 of 7
May+12.39%+9.62%6 of 7
June−6.84%−7.09%1 of 7
July+6.84%+7.22%5 of 7
August+1.65%+0.57%4 of 8
September−1.86%−0.48%4 of 8
October−1.20%−2.38%3 of 8
November+0.67%−1.57%3 of 7
December+1.99%−1.61%3 of 7

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Uniphar and its competitors

With revenue of EUR 3.1 billion in its latest fiscal year, Uniphar plc runs a healthcare services business spanning three divisions: Uniphar Medtech, Uniphar Pharma and Uniphar Supply Chain & Retail. Uniphar Medtech handles sales, marketing, servicing, quality and regulatory support for medical device makers, while Uniphar Pharma offers services across the life cycle of medicines, including access to products that are hard to source through conventional channels.

Headquarters
Dublin, Ireland
Employees
3,500
Founded
1967
Chief executive
Gerard Rabbette
Uniphar and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
UnipharUPR$1.23B2.9%21.4−0.23%
NEUCANEU$796.59M2.0%16.5−0.85%
Asker Healthcare GroupASKER$2.84B6.7%37.8−6.65%
AmplifonAMP$3.84B10.3%35.7+8.42%
GalenicaGALE$5.42B4.8%28.2+11.17%
Sinopharm Group Ltd H1099$6.63B3.0%6.59−5.15%

Same industry or related industries, similar size. Compare Uniphar with its competitors · Full profile